Blocking Peptide Fragment - Toyobo

BPF-301ExamplesAbsorbance at 450nm0.070.060.050.040.030.020.010.5mg/ml BPF-301 LotA0.5mg/ml BPF-301 LotB10mg/ml BSAAbsorbance at 450nm0.500.450.400.350.300.250.7mg/ml BPF-3012.4mg/ml BSA0.0050 25 12.5 6.25Peroxidase conc. (g/ml)0.200 30 60 90 120 150 180Blocking Time (min)Fig.1. BPF-BSA Comparison: Blocking EfficiencyPeroxidase solutions containing BPF-301 or BSA were added to 96wells polystyrene plate. The plate was incubated at 37 for 1hr andthen washed with 0.02% Tween20. The blocking performance wasevaluated by measuring the peroxidase activities retained onpolystyrene plate. The lower absorbance shows the higher blockingperformance. Blocking performance of BPF-301 is much higher thanthat of BSA.Fig.2. BPF-BSA Comparison: Blocking TimeBPF-301 or BSA solution was added to 96 wells polystyrene plate.The plate containing these blocking reagent was incubated at 4 for5180 minutes, and then washed with 0.02% Tween20. Theblocking performance was measured by human serum and antihumanIgG goat antibody POD conjugate system. Operation timerequired for blocking reaction is shorter than that of BSA.Absorbance at 450nm0.90.80.70.60.50.40.30.20.10.7mg/ml BPF-3012.4mg/ml BSA0.00 1 2 3 4 5 6hCEA conc. (ng/ml)Absorbance at 450nm0.070.060.050.040.030.020.010.0020259370 1 2 3 4 5 6Period (months)7Fig.3. BPF-BSA Comparison: Measuring sensitivityBPF-301 or BSA was used as a blocking reagent in ELISA assay fordetection of hCEA. It was shown that no interference on ELISA assaywas found in BPF-301.Fig.4. Stability (Powder form)Blocking performance was measured by the method mentioned inFig.1.

BPF-301PP PP PPP

BPF-301P P PP